Azitra, Inc. (AZTR) SEC filings

AZTRNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30

$0.61−0.06 (-8.99%)

Close on Nov 13, 2026Market cap $3.69MP/E –Yield –

SEC filings

40 of Azitra's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Oct 29, 2026	Oct 29, 2026	SEC EDGAR
Current report	8-K	Oct 26, 2026	Oct 26, 2026	SEC EDGAR
Current report	8-K	Oct 22, 2026	Oct 22, 2026	SEC EDGAR
Current report	8-K	Oct 1, 2026	Oct 1, 2026	SEC EDGAR
Current report	8-K	Sep 28, 2026	Sep 28, 2026	SEC EDGAR
Current report	8-K	Sep 8, 2026	Sep 8, 2026	SEC EDGAR
Current report	8-K	Aug 21, 2026	Aug 21, 2026	SEC EDGAR
Current report	8-K	Aug 12, 2026	Aug 12, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Jul 15, 2026	Jul 15, 2026	SEC EDGAR
Current report	8-K	Jun 17, 2026	Jun 17, 2026	SEC EDGAR
Current report	8-K	Jun 15, 2026	Jun 16, 2026	SEC EDGAR
Current report	8-K	Jun 4, 2026	Jun 4, 2026	SEC EDGAR
Current report	8-K	May 27, 2026	May 27, 2026	SEC EDGAR
Current report	8-K	May 13, 2026	May 13, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 13, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 8, 2026	May 8, 2026	SEC EDGAR
Current report	8-K	Mar 18, 2026	Mar 23, 2026	SEC EDGAR
Current report	8-K	Mar 13, 2026	Mar 13, 2026	SEC EDGAR
Current report	8-K	Mar 4, 2026	Mar 5, 2026	SEC EDGAR
Current report	8-K	Feb 27, 2026	Feb 27, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 27, 2026	SEC EDGAR
Current report	8-K	Feb 6, 2026	Feb 6, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jan 2, 2026	Jan 2, 2026	SEC EDGAR
Current report	8-K	Dec 16, 2025	Dec 17, 2025	SEC EDGAR
Current report	8-K	Nov 24, 2025	Nov 25, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 12, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Oct 1, 2025	Oct 3, 2025	SEC EDGAR
Current report	8-K	Aug 26, 2025	Aug 29, 2025	SEC EDGAR
Current report	8-K	Aug 20, 2025	Aug 20, 2025	SEC EDGAR
Current report	8-K	Aug 11, 2025	Aug 11, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 11, 2025	SEC EDGAR
Current report	8-K	Jul 3, 2025	Jul 3, 2025	SEC EDGAR
Current report	8-K	Jun 23, 2025	Jun 23, 2025	SEC EDGAR
Current report	8-K	Jun 18, 2025	Jun 18, 2025	SEC EDGAR
Current report	8-K	May 13, 2025	Jun 17, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Azitra's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Nov 12, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AZTR.

Compare: AZTR vs SYBX · AZTR vs GNLX · AZTR vs KPRX · AZTR vs CRVO · AZTR vs SKVI

Revenue growth-100.0% · median -49.9%

Company	Revenue	Growth
SKVI	$20.00K	0.0%
CRVO	$8.73K	-99.9%
AZTR	$0	-100.0%
SYBX	$0	–
GNLX	–	–
KPRX	–	–

Company

Next earnings (est.): Feb 26, 2027, after close
Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 13
Held by institutions: 35.7%
Auditor: GRASSI & CO., CPAs, P.C.
SEC CIK: 1701478

Advertisement
300 × 250

See a number that looks wrong?